Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Anidulafungin (Eraxis) vs Corticorelin (Acthrel)
An educational, source-based comparison of Anidulafungin (Eraxis) and Corticorelin (Acthrel) — how each peptide works, what it's researched for, and what to know before going deeper.
Echinocandin lipopeptide for invasive Candida infections.
Semisynthetic lipopeptide that non-competitively inhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesis in Candida and Aspergillus species.
- Candidemia and other invasive candidiasis
- Esophageal candidiasis
- • FDA-approved.
- • No dose adjustment for renal/hepatic impairment.
- • Infusion-related reactions possible.
Synthetic ovine CRH for differential diagnosis of Cushing's syndrome.
Synthetic ovine corticotropin-releasing hormone (oCRH) that stimulates pituitary ACTH release; used in inferior petrosal sinus sampling and peripheral CRH stimulation testing to distinguish pituitary from ectopic ACTH-dependent Cushing's syndrome.
- Differential diagnosis of ACTH-dependent Cushing's syndrome
- • FDA-approved.
- • Transient flushing, dyspnea, hypotension possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Anidulafungin (Eraxis) | Anidulafungin vs fluconazole in invasive candidiasis | NEJM | 2007 | Superior clinical response in invasive candidiasis. |
| Corticorelin (Acthrel) | CRH stimulation and IPSS in Cushing's | JCEM | 1991 | Improved discrimination of pituitary vs ectopic ACTH sources. |
Side-effect & safety grid
- FDA-approved.
- No dose adjustment for renal/hepatic impairment.
- Infusion-related reactions possible.
- FDA-approved.
- Transient flushing, dyspnea, hypotension possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Anidulafungin (Eraxis) vs Corticorelin (Acthrel) — Key differences
- Class: Anidulafungin (Eraxis) is classified as Echinocandin · Antifungal, while Corticorelin (Acthrel) is CRH Analog · Diagnostics.
- Primary research focus: Anidulafungin (Eraxis) — candidemia and other invasive candidiasis; Corticorelin (Acthrel) — differential diagnosis of acth-dependent cushing's syndrome.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Diagnostics.